Press Releases

Month Year

Jun 29, 2022

Sanofi to lower out-of-pocket cost of insulin for uninsured patients and expand access in underserved communities

Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins
Jun 22, 2022

Sanofi Statement on ACIP 2022-2023 Influenza Recommendations for People 65+
Jun 22, 2022

Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older

Results of nationally representative survey come as the ACIP evaluates data to provide guidance for flu vaccines in this vulnerable population
Jun 7, 2022

FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Jun 7, 2022

Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing
Jun 3, 2022

Provention Bio Announces the Grant of Inducement Awards
Jun 3, 2022

Provention Bio to Present at the Jefferies Global Healthcare Conference
Jun 3, 2022

Provention Bio Announces Update to Board of Directors
Jun 2, 2022

Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab-rwlc)

Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo
Jun 1, 2022

FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA

Show per page

Print
Email page
RSS